357
Productivity & Workflow354
Software Development248
Automation & Workflow238
Marketing & Growth204
AI Infrastructure & MLOps197
Photography & Imaging166
Writing & Content Creation193
Design & Creative170
Data & Analytics165
Customer Support156
Education & Learning144
Voice & Speech130
Sales & Outreach132
Operations & Admin119
Isomorphic Labs, spun out of DeepMind, raised $5B to develop its AI drug design work and advance drug candidates toward clinical trials.
In short: Isomorphic Labs has raised $5 billion to help take its drug candidates into clinical trials.
Isomorphic Labs, a drug research company that uses AI, has raised $5 billion in a Series C funding round. The company was spun out of Google’s DeepMind in 2021.
The funding round was co-led by Greenoaks and Sequoia Capital. A new investor, Andreessen Horowitz, also joined. Existing backers, including Alphabet’s venture arms GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.
Isomorphic says it is building an “AI drug-design engine.” In simple terms, it uses computer models to test many possible drug ideas quickly, like running lots of lab “what if” experiments in a simulator before doing them in real life. The company said it has seen “positive preclinical results” in oncology and immunology. Preclinical means early testing that happens before a drug is tried in people.
Isomorphic has also made deals with large drug companies, including Eli Lilly, Novartis, and Johnson and Johnson. The company said the new money will help it keep improving its system and expand into more areas of medicine.
New medicines usually take years and cost a lot to develop, and many ideas fail before they ever help patients. Tools that can narrow down which drug candidates are worth testing could save time and money, but the biggest proof still comes in clinical trials (tests in people). This funding signals that investors think Isomorphic is ready to take more of its work from computer and lab stages into human testing.
Source: TechCrunch AI